Article Sidebar
Published:
Apr 30, 2018Article Details
Copyright remains in the Author’s name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [forthcoming].
Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The SAMJ does not hold itself responsible for statements made by the authors.
Previously published images
If an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.
Main Article Content
The management of Wilms' tumour
Abstract
This report is based essentially on 45 patients with Wilms' tumour treated during the period 1951 - 1967 with comments on a modified regime in 20 patients treated since 1968.
During the period 1951 - 1967 the standard treatment was nephrectomy and radiotherapy; cy:oxics were added from 1959. The over-all long-term survival was 42%, but all infants under the age of 1 Year have survived. Cytoxics increased the over-all survival rate from 19% to 55%. Although we aimed at giving post-operative irradiation only, 10 patients received pre-operarve therapy because of the enormous size of their tumours and/or malnutrition. Eight of these patients have survived.
In view of the above, all patients, excepting infants under 1 year, have received pre- and postoperative X-ray therapy since 1968. We have also modified the cytoxic regime and all patients have been given repeated courses of actinomycin 0, while those with metastases or recurrence have also received vincristine. The over-all survival rate to date is 60%.
